Genelux CORP Form 4 insider transactions

Director John W. Smither reports the acquisition and disposal of Genelux Corp common stock and warrants.

Director Thomas John of Genelux Corp reports the acquisition of common stock and warrants, along with a commitment to resolve a potential short-swing profit liability.

Director Mary Mirabelli reports the acquisition and disposal of common stock and warrants of Genelux Corp on May 29, 2024.

VP of Clinical Trial Operations at Genelux Corp, Yu Yong, reports the acquisition and disposal of common stock and warrants, addressing a potential short-swing profit liability.

Genelux Corporation's CEO, Thomas Zindrick, reports the acquisition of 200,000 shares of common stock and accompanying warrants.

Ralph Smalling, Head of Regulatory at Genelux Corp, reports the acquisition and disposal of common stock and warrants.

Sean Ryder, General Counsel of Genelux Corp, reports the acquisition of 10,000 shares of common stock and warrants to purchase 10,000 shares.

Genelux Corp's CFO, Lourie S. Zak, reports acquiring and disposing of 31,250 shares of common stock and warrants.

Aladar Szalay, a director at Genelux Corp, reported selling shares of common stock in a series of transactions between May 13 and May 15, 2024.

Director Aladar Szalay of Genelux Corp reports selling shares in multiple transactions on May 7th and 8th, 2024.

Director Aladar Szalay reports selling shares of Genelux Corp common stock across multiple transactions from April 29 to May 1, 2024.

Director Aladar Szalay reports selling Genelux Corp shares in multiple transactions between April 22 and April 24, 2024.

Director Aladar Szalay reports selling shares of Genelux Corp on April 16 and 17, 2024, reducing his beneficial ownership.